CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionGross margin is 3.4%, lower than 95% of its Biotechnology peers (median 67.2%)
- FinancialsAltman Z-Score 3.9: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
5.09BCNY759.55M · vs all stocks (USD)
Revenue (TTM)
269.63MCNY40.25M · vs all stocks (USD)
Profit Margin
-86.01%vs Biotechnology peers
Beta
0.4790xvs all stocks
52-Week Change
-3.80%vs all stocks
Market Capitalization
5.09BCNY759.55M · vs all stocks (USD)
Enterprise Value
4.66BCNY695.01M · vs all stocks (USD)
Forward P/E
-39.15xvs Biotechnology peers
Price to Sales (TTM)
16.80xvs Biotechnology peers
Price to Book (MRQ)
3.36xvs Biotechnology peers
Enterprise to Revenue
17.27xvs Biotechnology peers
Enterprise to EBITDA
-37.53xvs Biotechnology peers
Gross Margin
3.43%vs Biotechnology peers
Profit Margin
-86.01%vs Biotechnology peers
Operating Margin
-66.23%vs Biotechnology peers
Return on Assets (TTM)
-6.69%vs Biotechnology peers
Return on Equity (TTM)
-16.29%vs Biotechnology peers
Revenue (TTM)
269.63MCNY40.25M · vs all stocks (USD)
Revenue per Share (TTM)
0.4280CNYUpdated Sep 22, 2026Quarterly Revenue Growth
6.30%vs Biotechnology peers
Gross Profit (TTM)
-35.51MCNY-5.30M · vs all stocks (USD)
EBITDA (TTM)
-124.06MCNY-18.52M · vs all stocks (USD)
Net Income (TTM)
-231.91MCNY-34.62M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.33%vs Biotechnology peers
Operating Cash Flow (TTM)
-97.01MCNY-14.48M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-176.36MCNY-26.33M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
7.68KCNYFY2025 · Dec 31, 2025Revenue
267.70MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
306.57MCNYFY2025 · Dec 31, 2025Gross Profit
-38.87MCNYFY2025 · Dec 31, 2025Operating Income
-206.26MCNY-30.79M · vs all stocks (USD)
Pre-tax Income
-233.08MCNYFY2025 · Dec 31, 2025Income Tax Expense
1.73MCNYFY2025 · Dec 31, 2025Net Income
-234.81MCNYFY2025 · Dec 31, 2025EBIT
-224.47MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-100.97MCNYFY2025 · Dec 31, 2025Research & Development
48.75MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
23.22MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.61MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
635.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
635.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-234.81MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-252.40KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-254.51MCNYFY2025 · Dec 31, 2025Free Cash Flow
-379.43MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
290.55MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-234.81MCNYFY2025 · Dec 31, 2025Other Non-cash Items
11.36MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-33.99MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.94MCNYFY2025 · Dec 31, 2025Capital Expenditures
-124.92MCNYFY2025 · Dec 31, 2025Net Acquisitions
-116.92KCNYFY2025 · Dec 31, 2025Purchase of Investments
-314.00MCNYFY2025 · Dec 31, 2025Sale of Investments
315.12MCNYFY2025 · Dec 31, 2025Other Investing Activity
13.38MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-110.53MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
280.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-101.04MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.35MCNYFY2025 · Dec 31, 2025Other Financing Charges
-101.80MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
68.80MCNYFY2025 · Dec 31, 2025Shares Outstanding
649.04MSharesUpdated Sep 22, 2026Float Shares
452.25MSharesUpdated Sep 22, 2026% Held by Insiders
28.17%vs all stocks
% Held by Institutions
9.65%vs all stocks
Total Cash (MRQ)
196.38MCNY29.31M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3120CNYUpdated Sep 22, 2026Total Debt (MRQ)
451.35MCNY67.37M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3447xvs Biotechnology peers
Current Ratio (MRQ)
1.21xvs Biotechnology peers
Book Value per Share (MRQ)
2.08CNYUpdated Sep 22, 2026Total Assets
2.09BCNY312.24M · vs all stocks (USD)
Total Current Assets
547.16MCNYFY2025 · Dec 31, 2025Total Liabilities
683.69MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.54BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
239.73MCNYFY2025 · Dec 31, 2025Total Current Liabilities
443.95MCNYFY2025 · Dec 31, 2025Cash
286.20MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
292.59MCNYFY2025 · Dec 31, 2025Accounts Receivable
93.59MCNYFY2025 · Dec 31, 2025Inventory
69.12MCNYFY2025 · Dec 31, 2025Accounts Payable
95.30MCNYFY2025 · Dec 31, 2025Short-term Debt
275.02MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.96MCNYFY2025 · Dec 31, 2025Long-term Debt
145.42MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
19.85MCNYFY2025 · Dec 31, 2025Common Stock (Book)
649.04MCNYFY2025 · Dec 31, 2025Retained Earnings
-600.35MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.41BCNY210.19M · vs all stocks (USD)
Treasury Stock
100.00MCNYFY2025 · Dec 31, 202552-Week Low
5.01CNYUpdated Sep 22, 202652-Week High
8.46CNYUpdated Sep 22, 202652-Week Change
-3.80%vs all stocks
Beta
0.4790xvs all stocks
50-Day MA
6.51CNYUpdated Sep 22, 2026200-Day MA
6.68CNYUpdated Sep 22, 2026Avg 10-Day Volume
17.05MSharesUpdated Sep 22, 2026Avg 30-Day Volume
28.22MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.3700CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 3.4%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 0.03Industry median: 0.67Industry P5: 0.14Peers compared: 260
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 16.80Revenue Growth YoY: 0.06
Financial Health
Altman Z-Score 3.9: safe zoneNotable
Altman Z-Score: 3.90
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
QuidelOrtho Corporation
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule